<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486326</url>
  </required_header>
  <id_info>
    <org_study_id>2020P-000464</org_study_id>
    <nct_id>NCT04486326</nct_id>
  </id_info>
  <brief_title>Crofelemer for Functional Diarrhea</brief_title>
  <official_title>Crofelemer for Functional Diarrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the clinical response of patients with
      diarrhea to crofelemer relative to placebo and evaluate the overall safety and tolerability
      of crofelemer in the treatment of diarrhea.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bristol Stool Score</measure>
    <time_frame>week 8</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>crofelemer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crofelemer</intervention_name>
    <description>Crofelemer</description>
    <arm_group_label>crofelemer</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>mytesi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is a man or woman aged 18 to 65 years, inclusive, at Screening.

          2. Patient has functional diarrhea defined by the Rome IV criteria as loose (mushy) or
             watery stools ≥25% and hard or lumpy stools &lt;25% of bowel movements

          3. Patient has had a colonoscopy performed:

               1. Within 10 years prior to Prescreening if patient is at least 50 years of age
                  (alternatively, a flexible sigmoidoscopy, double contrast barium enema, or CT
                  colonography within the past 5 years is acceptable [see recommendations of the
                  American Cancer Society])

               2. Since the onset (if applicable) of any of the following alarm features for
                  patients of any age (see Spiller and Thompson, 2010 - i.e. Patient has documented
                  weight loss within the past 6 months; Patient has nocturnal symptoms; Patient has
                  a familial history of colon cancer; or patient has blood mixed with their stool
                  (excluding any blood from hemorrhoids).

          4. Patient has an average daily stool consistency score (BSS) of ≥5.5 on days without the
             use of an anti-diarrheal and at least 3 days with a BSS score ≥5 on a 1 to 7 scale
             over the week prior to randomization.

          5. Patient has completed the daily diary on at least 6 of the 7 days during the week
             prior to randomization AND at least 11 of the 14 days during the 2 weeks prior to
             randomization.

          6. Patient has not used loperamide rescue medication more than 4 days during the
             screening period.

          7. Patient is not planning to change his/her usual diet and lifestyle during the course
             of the study.

          8. Patient is willing to be compliant with study procedures including completing the
             daily diary during the screening period and throughout the study.

          9. Patient must sign an informed consent document before the initiation of any
             study-related procedures indicating that he or she understands the purpose of and
             procedures required for the study and is willing to participate in the study.

        Exclusion Criteria:

          1. Patient has a history of inflammatory or immune-mediated GI disorders including
             inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis, microscopic
             colitis) and celiac disease.

          2. Patient has a predominant symptom of abdominal pain.

          3. Patient has a history of diverticulitis within 3 months prior to screening. Patients
             with a history of diverticulosis are candidates for the study.

          4. Patient has a history of intestinal obstruction, stricture, toxic megacolon, GI
             perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic
             colitis, or impaired intestinal circulation (eg, aortoiliac disease).

          5. Patient has any of the following surgical history:

               1. Any abdominal surgery within the 3 months prior to screening; or

               2. Patient has a history of major gastric, hepatic, pancreatic, or intestinal
                  surgery (appendectomy, cholecystectomy, hemorrhoidectomy, or polypectomy greater
                  than 3 months are allowed). For the purposes of this study, laparoscopic
                  surgeries without complication are considered minor and non-exclusionary,
                  provided the condition for which the surgery was performed was not exclusionary.

          6. Patient has an unstable renal, hepatic, metabolic, or hematologic condition.

          7. Patient has a history of human immunodeficiency virus infection.

          8. Patient has a history of DSM-IV-TR-defined substance dependency, excluding nicotine
             and caffeine, within 2 years prior to Prescreening.

          9. Patient has a history of alcohol abuse as defined by DSM-IV-TR, binge drinking as
             defined by the National Institutes on Alcohol Abuse and Alcoholism, or any medical
             treatment for alcohol-related co-morbidities, within 5 years prior to Prescreening.
             Recovered alcoholics who have not consumed alcohol over the 5 years prior to
             Prescreening are candidates for the study.

         10. Patient has current (within 14 days of randomization) or expected use of any narcotic
             or opioid containing agents, tramadol

         11. Patient is unable to swallow solid, oral dosage forms whole with the aid of liquid
             (patients may not chew, divide, dissolve, or crush the study drug).

         12. Patient has received an investigational drug or used an investigational medical device
             within 30 days prior to randomization.

         13. Patient has a known pregnancy or is breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Lembo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vivian Cheng, MS, MPH</last_name>
    <phone>617.667.0682</phone>
    <email>vcheng2@bidmc.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Anthony Lembo</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

